Abstract B085: Preclinical pharmacokinetic/pharmacodynamic (PK/PD) relationship demonstrated for BVD-723, a potent and selective phosphoinositide 3-kinase gamma (PI3Kγ) inhibitor

Deborah Knoerzer; Martin Teresk; Peter Krutzik; Erika O’Donnell; Gary DeCrescenzo; Dean Welsch; Caroline Emery

doi:10.1158/1535-7163.TARG-17-B085

Pharmacokinetics and Pharmacodynamics

Abstract B085: Preclinical pharmacokinetic/pharmacodynamic (PK/PD) relationship demonstrated for BVD-723, a potent and selective phosphoinositide 3-kinase gamma (PI3Kγ) inhibitor

Deborah Knoerzer, Martin Teresk, Peter Krutzik, Erika O’Donnell, Gary DeCrescenzo, Dean Welsch and Caroline Emery

Deborah Knoerzer

1BioMed Valley Discoveries, Kansas City, MO;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Martin Teresk

1BioMed Valley Discoveries, Kansas City, MO;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Peter Krutzik

2Primity Bio, Fremont, CA.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Erika O’Donnell

2Primity Bio, Fremont, CA.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Gary DeCrescenzo

1BioMed Valley Discoveries, Kansas City, MO;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Dean Welsch

1BioMed Valley Discoveries, Kansas City, MO;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Caroline Emery

1BioMed Valley Discoveries, Kansas City, MO;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

DOI: 10.1158/1535-7163.TARG-17-B085 Published January 2018

Article
Info & Metrics

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: January 2018 to February 2021

	Abstract	Full-text HTML	PDF
Total	667	0	0

Cited By

Article Information

Volume 17, Issue 1 Supplement, pp. B085

DOI

https://doi.org/10.1158/1535-7163.TARG-17-B085

Published By

American Association for Cancer Research

Print ISSN

1535-7163

Online ISSN

1538-8514

Author Information

Deborah Knoerzer1,
Martin Teresk1,
Peter Krutzik2,
Erika O’Donnell2,
Gary DeCrescenzo1,
Dean Welsch1, and
Caroline Emery1

¹BioMed Valley Discoveries, Kansas City, MO;
²Primity Bio, Fremont, CA.

Molecular Cancer Therapeutics: 17 (1 Supplement)

January 2018
Volume 17, Issue 1 Supplement

Table of Contents

Search for this keyword

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Abstract B085: Preclinical pharmacokinetic/pharmacodynamic (PK/PD) relationship demonstrated for BVD-723, a potent and selective phosphoinositide 3-kinase gamma (PI3Kγ) inhibitor

Message Subject (Your Name) has forwarded a page to you from Molecular Cancer Therapeutics

Message Body (Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

Abstract B085: Preclinical pharmacokinetic/pharmacodynamic (PK/PD) relationship demonstrated for BVD-723, a potent and selective phosphoinositide 3-kinase gamma (PI3Kγ) inhibitor

Deborah Knoerzer, Martin Teresk, Peter Krutzik, Erika O’Donnell, Gary DeCrescenzo, Dean Welsch and Caroline Emery

Mol Cancer Ther January 1 2018 (17) (1 Supplement) B085; DOI: 10.1158/1535-7163.TARG-17-B085

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Abstract B085: Preclinical pharmacokinetic/pharmacodynamic (PK/PD) relationship demonstrated for BVD-723, a potent and selective phosphoinositide 3-kinase gamma (PI3Kγ) inhibitor

Deborah Knoerzer, Martin Teresk, Peter Krutzik, Erika O’Donnell, Gary DeCrescenzo, Dean Welsch and Caroline Emery

Mol Cancer Ther January 1 2018 (17) (1 Supplement) B085; DOI: 10.1158/1535-7163.TARG-17-B085

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
Info & Metrics

Cited By...

Pharmacokinetics and Pharmacodynamics

Abstract LB-C01: The kinase polypharmacology landscape of clinical PARP inhibitors
Abstract C009: Clinical pharmacokinetic and pharmacodynamic analyses support biological effectivity of the PARP inhibitor olaparib as radiosensitizer at low doses

Show more Pharmacokinetics and Pharmacodynamics

Pharmacokinetics and Pharmacodynamics: Poster Presentations - Proffered Abstracts

Abstract LB-C01: The kinase polypharmacology landscape of clinical PARP inhibitors
Abstract C009: Clinical pharmacokinetic and pharmacodynamic analyses support biological effectivity of the PARP inhibitor olaparib as radiosensitizer at low doses
Abstract B083: Population pharmacokinetics and pharmacodynamics for an oral Notch inhibitor, LY3039478, in patients with advanced cancer and healthy volunteers

Show more Pharmacokinetics and Pharmacodynamics: Poster Presentations - Proffered Abstracts

Main menu

User menu

Search

Abstract B085: Preclinical pharmacokinetic/pharmacodynamic (PK/PD) relationship demonstrated for BVD-723, a potent and selective phosphoinositide 3-kinase gamma (PI3Kγ) inhibitor

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: January 2018 to February 2021

Cited By

Article Information

Author Information

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Pharmacokinetics and Pharmacodynamics

Pharmacokinetics and Pharmacodynamics: Poster Presentations - Proffered Abstracts

Articles

Info for

About MCT